After 20 something years of living a diverse educational and professional life motivated by healthy lifespan extension and dominated by science and technology I have reached the riskiest and most rewarding phase: launching a business around it and making it real. I have founded a startup, called AgeCurve Limited and we are already offering a product,… Continue reading AgeCurve Limited and Gen P: my business angle on aging and longevity
A snippet from the following interview: The Regeneration Generation: A Conversation With Bob Hariri, Vice-Chairman and Co-Founder of Human Longevity Inc.
The Wall Street Journal Patent Board Biotechnology Scorecard was published this week in which biotech companies & private research firms are grouped by their Patent Board science strength ranking “which is based on the scale, quality, impact, and nearness to core science of a company’s patent-based intellectual property”. What I found interesting at the first… Continue reading Patent Board science strength of biotech firms in WSJ
The pioneer biological video publishing site JoVE (covered here many times) will soon launch a blogging platform and a community site. Nikita Bernstein, the main nerd behind JoVE is building the code and the platform – as Anne Kushnir informed me – should hopefully go live in the next couple of weeks. At least that… Continue reading Will JoVE’s new science blog service reinvent the genre?
Different attitudes, same endeavors. 1. The folks at the California Institute of Regenerative Medicine (CIRM) started to offer grants for biotech companies up to $55,000 out of the 3 billion ‘hope’ dollars. San Diego Union Tribune: Industry and academia team up: For the first time in its three-year existence, the state taxpayer-funded stem cell institute… Continue reading CIRM and NIH stem cell grants to the biotech industry
Elrond: Strangers from distant lands, friends of old you have been summoned here to answer the threat of Mordor. Middle Earth stands upon the brink of destruction, none can escape it. You will unite or you will fall. Each race is bound to this fate, this one doom. Bring forth the ring, Frodo. [Frodo puts… Continue reading Web entrepreneurs and biotech: strangers from distant lands
Linda Powers is the managing director and co-founder of Toucan Capital Corp, a $120 million venture capital fund (SBIC) focused on seed and early-stage life science and advanced technology investments (the fund markets itself as the The Leading US Investor in Stem Cells and Regenerative Medicine). Out of here insights and facts presented on the… Continue reading SENS3: The stem cell marketplace by Linda Powers, Tucan Capital (slides)
In the age of compelling technology analogies and nomenclatures it was unavoidable that somebody at last identifies enough differences in the history of industrial regenerative medicine to tell Regenerative Medicine 1.0 from 2.0. The man behind is Chris Mason, Group Leader of Stem Cell + Regenerative Medicine Bioprocessing Unit, University College London and cofounder and… Continue reading Are we really in the age of Regenerative Medicine 2.0? A comparison by Chris Mason
Check out Business 2.0’s 100 fastest growing tech companies and read the excellent little summaries on the first 25 out of which 5 are medical related. In regenerative medicine LifeCell has a high position with competitors like Genentech (here think about the recent 23andMe story), Amgen Inc, Gilead Sciences.
Business 2.0 Blog Beta Network‘s new blog BioTech(nically) was launched written by Marie Cannizzaro who says about herself in the intro post, March 27: “Before joining Business 2.0, I wrote for Dow Jones VentureWire and Stanford Magazine. I have a degree in Human Biology with a concentration in Biotechnology and Bioethics from Stanford University.” At… Continue reading BioTech(nically), Business 2.0’s new biotech blog
Research and Markets has announced the addition of Regenerative Medicine – Global Strategic Business Report to their offering for EUR 3,407.00. Link “This report analyzes the worldwide markets for Regenerative Medicine in Millions of US$. The report provides separate comprehensive analytics for the US, Japan, Europe, Canada, and Asia-Pacific, and Rest of World. Annual forecasts… Continue reading Technological breakthroughs in Regmed according to a Global Strategic Business Report
Well, I am pleased to announce that we’ve just entered into an era of online scientific video sharing as there exists now a nascent niche market around. After the first mover JoVE (Journal of Visualized Expermients, covered many times here), LabAction.com was launched on 21st March 07 with as many as 3 biology-related videos. And… Continue reading LabAction.com: new player on the science video niche market
The recent Carnival of Biotechnology is hosted on Babybiotechs and is rather industry and business oriented which is a good sign of a more mature industry. Check the posts and form an opinion.
Ok, this is the question I asked yesterday at LinkedIn Question&Answers service: How much do you think a scientific blogpost article of 300 words is worth (in US dollars)?
Yesterday I shot Nasdaq on 4 Times Square Plz. Do you know how many public, stem cell-related, biotech companies are included in the Nasdaq Biotechnology Index? You can check that.
Such a Californian story: Lorry I. Lokey, the founder of Business Wire will give a minimum of $33 million to help build a home for Stanford’s Institute for Stem Cell Biology and Regenerative Medicine. Lokey says: “The important thing to me is that stem cells might not only extend life, but also improve the quality… Continue reading 80 year old Lokey’s $33 million donation for Stanford Stem Cell Labs
Stem cell therapies are likely to be disruptive treatments for the following medical sectors according to the Stem Cell Market Analysis Fact Sheet: What is interesting in the following list: all the target tissues are of mesodermal origin. • Total knee implants: Stem cell therapies that repair worn articular or meniscus cartilage will delay and… Continue reading Disruptor candidate stem cell therapies
Did you ever think that the market value of all public stem cell companies is $1.655 billion, which is exactly (+5 million) the amount of money Google Acquired YouTube in a stock-for-stock transaction in October, 2006? This fact sheds new light on the maturity of the information technology and biotechnology markets. Let’s make hypes into… Continue reading All American Stem Cell Companies = 1 YouTube = $1.65 billion
This extrapolation is from the inforich and insider Stem Cell Market Analysis Fact Sheet of the 2nd Annual Stem Cell Summit, February 12-13 at San Diego, happening now. Other important facts concerning the Stem Cell Therapy Market in the U.S.:
23andMe is a biotech focused web startup based in Mountain View, California (yes, the Googleplex neighbourhood) self-defined as “an early stage startup developing tools and producing content to help people make sense of their genetic information. Our goal is to take advantage of new genotyping technologies and help consumers explore their genetics, informed by cutting… Continue reading 23andMe: the early bird of web based biotech startups
Truth to be told I am not really interested in the Resveratrol story neither as a researcher nor as a life extension supporter. First, it is about classical pharmacology, seeking the molecular targets of a relatively simple molecule back and forth, testing its effect on different animals with standard setups, no hint at a new… Continue reading Resveratrol goes to the clinic: a Pulitzer for David Stipp!
Here is one slide from my presentation yesterday introducing the merits of Cambridge, UK from a biological, biotechnological point of view:
Insightful, inforich and überoptimistic interview by David Morrill with Matt Gardner on the Bay Area and the broader Northern California Biotech Cluster. Gardner is the president of BayBio, an independent, non-profit 501(c)(6) trade association serving the life science industry in Northern California. Gardner helped author BayBio: Impact 2007, a new report in which he discussed… Continue reading Bay Area biotech prospects through BayBio Chief’s lenses
Forget about governmental funds for a minute. According to you which companies have the chance to develop an indefinite life extension technology? Let us assume that even today there exists a company, or a predecessor of it which can eventually realize indefinite LE and customize it. Will it be a biotech company, like Genentech, Geron,… Continue reading The first private company behind indefinite life extension: ?
And now for something completely different! Sometimes life is just simply life for me without any extension. This is Life.exe. So at the weekends during the largely dead webtimes, I’ll blog about other things than stem cells, regenerative medicine, maximum life extension and biotech. This week offstory is a report, which shows the transformation of… Continue reading Valley Brats in Rolling Stone’s Tech Issue: trends in journalism (weekend off)
David A Kekich is a heavyweight venture capitalist and investment expert. In 1999, he founded the Maximum Life Foundation, a corporation dedicated to curing aging related diseases. His LIVES™ financial strategy will finance the research needed to profitably develop life extending technologies. Kekich, who is also a lifestyle life extensionist, and very aware of current… Continue reading Maximum Life CEO David Kekich: the investment strategy of life extension
James Clement is an attorney and serial entrepreneur. He is the Chief Operating Officer of Maximum Life Foundation which supports aging and life extension research with a mature and secure VC fund strategy (next blogterviewee, David Kekich, C.E.O. of MaxLife). 1. What is the story of your life extension commitment? I have been interested in… Continue reading Maximum Life’s James Clement: what can a lawyer do for life extension?
Kevin Dewalt is an American technology professional, presently working at a VC. Kevin is a strong life extension supporter. We’ve met online at Baris Karadogan’s blog. I specially liked his “happy argument” for maximum life extension on the psychological level, see answer 3. 1. What is the story of your life extension commitment? When I… Continue reading Kevin Dewalt’s answers: technology professional, lifestyle life extensionist
There was a very interesting comment dialogue last week apropos of Aubrey de Grey‘s TED talk, and the host was Baris Karadokan’s blog called From Istanbul to Sand Hill Road subtitled High-tech, venture capital, creativity and innovation. Here are some details. Link storytelling idea source
There is a dense comment debate on Bodyhack for more than a week concerning the electoral Missouri Stem Cell Hunter issue, celebs with ESC pro- or contra ads. Here is an effective comment from today’s related post by the commenter named Orrin: “I wonder what would happen if Bill Gates invested 2 billion dollars to… Continue reading What would happen if Bill Gates invested 3 billion dollars to embryonic stem cell research?
Hello everybody, let me introduce myself: I am the first full-time biotechnologist at Google Inc. (well, not really). My job at Google is fascinating: I have to plan and build a comprehensive regenerative database/map of the complete human body which will be the input of the ultimate human regenerative software. It is so, because in… Continue reading First full-time biotech employee at Google BioLabs
From PharmaLive: Aldagen, Inc. and Innovative Micro Technology (IMT) today announced that they have formed an alliance to co-develop and commercialize a version of IMT’s Rare Cell Purification System, customized specifically for clinical cell therapies. This system, called the ALDESORTER(TM), will be used with Aldagen’s ALDESORT(R) product and is designed to isolate unique stem cell… Continue reading Yet another industrial stem cell alliance: Aldagen meets IMT
As I mentioned before, continuous regeneration treatment of the whole human body called Pimm could be interpreted as inside plastic surgery for functional reasons. And now here comes one nice example of the present biotech trend:
From Investor’s Business Daily: Big pharmaceutical firms and major biotechs are holding back as well, William Caldwell CEO of Advanced Cell Technology says. “While all of them have stem cell development labs someplace in the bowels of their organizations, they are not putting capital into the sector.” These companies are nervous about the political and… Continue reading U.S. stem cell companies: a new roundup
Deep story by Kerry Howley, associate editor of Reason Magazine, aka “Donor #15” who sold 12 ova to a pair of strangers for $10,000. From the story: By the mid-1980s, babies were being born via donated eggs that were fertilized outside the womb and later implanted in women incapable of producing viable ova. If you… Continue reading Human Egg Market: the naked truth
$16-million round of financing goes for Gamida Cell to bring StemEx, a treatment for leukemia and lymphoma to the market. From Red Herring: The funds will be used to expand the Israeli stem cell startup’s pipeline and bring products to market. …The company reported extremely favorable clinical results from phase I and II studies of… Continue reading $16Million Israeli fund for anti leukemia treatment StemEx
From SFGate: “Peter A. Thiel, co-founder and former chief executive officer of the online payments system PayPal, announced Saturday he is pledging $3.5 million “to support scientific research into the alleviation and eventual reversal of the debilities caused by aging.” The grant goes to the Methuselah Foundation a nonprofit volunteer organization founded by Aubrey de… Continue reading PayPal founder’s $3.5 million support goes for life extension purposes
When and for what reason will Google launch a biotech business, and why regenerative medicine? It is a big question what kind of company Google Incorporation plans to become beyond the core search engine and ad business. Google is a geek company founded by two extremely talented IT nerds. My guess is that for Google… Continue reading Google’s coming out in biotech: when and why?